Improving the utility of comorbidity records Retha Steenkamp UK Renal Registry.

Slides:



Advertisements
Similar presentations
UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.
Advertisements

UK Renal Registry 16th Annual Report Figure Data completeness for key variables, stratified by first modality HD = haemodialysis; PD = peritoneal.
UK Renal Registry 15th Annual Report Figure One year death rate per 1,000 patient years by UK country and age group for prevalent dialysis.
Simulation of “forwards-backwards” multiple imputation technique in a longitudinal, clinical dataset Catherine Welch 1, Irene Petersen 1, James Carpenter.
UK Renal Registry 16th Annual Report Figure 5.1. Flow chart showing number of patients included in the various analyses.
An update from The UK Renal Registry Dr Fergus Caskey Medical Director, UK Renal Registry Annual Informatics Meeting, September 2014.
Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
Chapter 5: Mortality 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Summary of the 2012 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2014.
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
EVIDENCE BASED MEDICINE
Readmission and Chronic illness that could benefit from end of life discussions.
Chronic kidney disease Mr James Hollinshead Public Health Analyst East Midlands Public Health Observatory (EMPHO) UK Renal Registry 2011 Annual Audit Meeting.
Rowan Walker – Chairman Chair: Steve Chadban ANZDATA update (Stephen McDonald) Analgaesic nephropathy – the end of an epidemic? (Sean Chang)
UKRR Annual Informatics Meeting, September 2013 Highlights from the 15 th Annual Report Rishi Pruthi Research Fellow UK Renal Registry.
Exploring centre variation in RRT provision Dr Clare Castledine UKRR clinical fellow.
Survival comorbidity Mrs Retha Steenkamp Senior Statistician UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
What comorbidity should we adjust for in RRT patients? James Fotheringham School of Health and Related Research.
Advanced CKD Study Daniel Ford UKRR Annual Audit Meeting June 2009.
The National Renal Dataset Charlie Tomson UKRR Annual Meeting 24 th June 2009.
Why your data matters? How it helps patients, the NHS and research? How do I get UKRR data for research? Dr Retha Steenkamp Senior Statistician, UKRR.
Haemodialysis Vascular Access: Recent Trends From ANZDATA Dr Kevan Polkinghorne Monash Medical Centre ANZSN September 2007.
UKRR Dataset v4.1 How does it fit with the UKRDC ACTIONS IN YOUR RENAL UNIT TO IMPLEMENT THE NEW DATASET UK RENAL REGISTRY 2015 INFORMATICS MEETING: DATA.
Data completeness reporting Alex Hodsman, David Bull, Paul Dawson UK Renal Registry.
UK Renal Registry 10th Annual Report 2007 Fig 3.1 Incident rates in the countries of the UK:
UK Renal Registry 17th Annual Report Figure 1.1. RRT incidence rates in the countries of the UK 1990–2013.
Chapter 10 Cancer 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Cancer Working.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Highlights from the Annual Report UK Renal Registry 2013 Annual Audit Meeting Dr Catriona Shaw Registrar, UK Renal Registry.
Survival after graft failure Dr Lynsey Webb Registrar UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
UKRR – HES linkage James Fotheringham Sheffield Kidney Institute.
Chapter 3 Mortality in End Stage Kidney Disease 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 6: Mortality.
Summary of the 2013 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2015.
UK Renal Registry 14th Annual Report Figure Consort diagram detailing incident RRT patients 2002–2006, HES admissions and ONS records included in.
Highlights from the Registry year and Annual Report Professor Terry Feest Assistant Director UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
UK Renal Registry 17th Annual Report Figure 4.1. RRT treatment used by prevalent paediatric patients
What happens to patients returning to dialysis after transplant failure? Data from the UK Renal Registry Dr Lynsey Webb 1, Dr Anna Casula 1, Dr Charlie.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
Obesity in the end stage kidney disease population
UK Renal Registry 13th Annual Report
2016 Annual Data Report, Vol 2, ESRD, Ch 6
First-year death rates by modality figure 8
Lynn Josephs, David Culliford, Matthew Johnson, Mike Thomas
Summary of the 2013 ERA-EDTA Registry Annual Report
UK Renal Registry 16th Annual Report
UK Renal Registry 18th Annual Report
UK Renal Registry 9th Annual Report 2006
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
UK Renal Registry 10th Annual Report 2007
UK Renal Registry 19th Annual Report
CHAPTER 5 Paediatric Renal Replacement Therapy
North west Regional Day
Presenter: Wen-Ching Lan Date: 2018/10/17
CHAPTER 3 DEATHS Stephen McDonald 2012 Annual Report—35th Edition
Fig 6.1 Frequency of ischaemic heart disease in incident patients
UK Renal Registry 16th Annual Report
UK Renal Registry 14th Annual Report
2013 Annual Report - 36th Edition
UK Renal Registry 15th Annual Report
UK Renal Registry 14th Annual Report
UK Renal Registry 14th Annual Report
UK Renal Registry 16th Annual Report
UK Renal Registry 12th Annual Report
UK Renal Registry 16th Annual Report
Nadia Howlader, PhD National Cancer Institute
Dialysis outcomes in Australia & New Zealand
Presentation transcript:

Improving the utility of comorbidity records Retha Steenkamp UK Renal Registry

Importance of comorbidities in patients on RRT Individual patient comorbidity and prognosis UK country and centre level comparisons and comorbidities International comorbidity comparisons

UK Renal Registry comorbidities 15 Comorbidities: Heart disease: angina, MI in past 3 months, MI >3 months ago, CABG/angioplasty, heart failure Non-cardiac vascular disease: cerebrovascular disease, claudication, ischaemic/neuropathic ulcers, amputation for PVD, non-coronary angioplasty/vascular graft Other: diabetes (not cause of ERF), liver disease, ‘smoking’, malignancy, COPD

Drawbacks of current comorbidity data Important comorbidities not collected: dementia and mobility Heart failure not collected by all centres Degree of severity not collected Smoking: current smoker, smoking within last year Malignancy

Recording of comorbidities Comorbidities are captured at start of renal replacement therapy (RRT) Manual data entry into the renal IT system Process of data entry varies by renal centre: –Directly entered by senior medical staff (consultant) –Entered from updated form by data management staff

Challenges in analysing UK Renal Registry comorbidity data Comorbidity completeness Renal IT systems Statistical challenges

Comorbidity completeness of incident patients, Number of renal centres Number of new patients4,1834,8275,4365,7276,0766,10732,356 Number of patients with comorbidity data 2,2712,4702,4982,5552,6732,44214,909 Percentage Median % for centres returning >0% comorbidity

Comorbidity recording, 1998 to 2006 Number of comorbidityNumber of% of records (out of total of 14)patients 0 (No data)24, < < < (Complete data)12,

Completeness of comorbidity recording by renal centre, incident patients

Renal IT systems Different renal centres have differing renal IT software systems Renal IT systems sometimes handle the capturing of comorbidities differently Comorbidity not filled out (blank) should mean that the comorbidity has not been collected, but not all IT systems have worked in this way

Statistical challenges Not adjusting for comorbidity might lead to inadequate case-mix adjustment Case-mix adjustment in statistical models are limited to complete cases - Loss of statistical power - Selection bias - Lack of generalisability Most standard statistical methods assumes complete data

Missing comorbidity data strategies Not adjusting for comorbidities at all to avoid the drop in patient numbers Restrict analysis to a subset of centres with ≥ 85% comorbidity returns Include other measures such as transplant wait listing status as a proxy for comorbid conditions Complete case analysis

Survival 1 year after 90 days by first treatment modality, age adjusted “ There appeared to be better one year survival on PD compared with HD after age adjustment; however, a straightforward comparison of the modalities may be misleading ”

1 year after 90 days survival, incident RRT patients, age adjusted

Incident patient survival across UK countries, , age adjusted SurvivalEnglandN IrelandScotlandWalesUK At 90 days % CI year after 90 days % CI “These data have not been adjusted for differences in primary renal diagnosis, ethnicity or comorbidity ”

Survival 1 year after 90 days for incident RRT patients in , adjusted for age, diagnosis and comorbidity

Variance explained by individual comorbidities, survival after 90 days

Additional variance explained, survival after 90 days

Unadjusted 1 year survival of incident RRT patients,

Unadjusted 1 year after 90 days survival of incident RRT patients,

Demographic comparison of patients with and without comorbidity returns

Improving comorbidity completeness Encourage clinicians to complete comorbidity returns Highlight the problems with case-mix adjustment National Renal Dataset HES linkage Ultimately work on a system that rewards clinicians returning comorbidity data by providing them with a prognostic survival prediction tool Missing data imputation

Prognostic survival prediction tool Difficult to accurately discuss prognostic information with patients Provide objective information to patients and their families Prognostic tool to predict early death will aid in decision making related to RRT

What is multiple imputation? Developed by Rubin in a survey setting as a statistical technique for analysing data sets with missing observations 1.Imputation: Missing values are replaced by imputations The imputation procedure is repeated many times with each dataset having the same observed values and different sets of imputed values for missing observations 1.Analyse using standard statistical methods 2.Pooling parameter estimates

Conclusion Comorbidity is an important predictor of outcome Important in explaining differences between centres and UK nations and important for individual prognosis Outcome differences between patients with and without comorbidity

Acknowledgements Many thanks to: UK renal centres and patients Data and systems staff (UKRR) Biostatisticians (UKRR) T Collier and D Nitsch at LSHTM